Medivation Reports Year-End 2007 Financial Results and Pipelin...( SAN FRANCISCO Feb. 19 /- Medivati...)

SAN FRANCISCO, Feb. 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its financial results and pipeline progress for the year ended December 31, 2007.

"In 2007 we continued our track record of milestone achievement to advance development across our entire portfolio, and we are pleased to enter 2008 with an Alzheimer's disease product candidate in confirmatory Phase 3 development," said David T. Hung, M.D., president and chief executive officer of Medivation. "We remain committed to the rapid, efficient development of our novel product candidates for Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer to make them available to people around the world who are increasingly afflicted with these deadly and debilitating diseases for which there are still very few treatment options."

Recent Accomplishments

Alzheimer's Disease

-- Completed a double-blinded, placebo-controlled twelve month extension

of our first pivotal Alzheimer's disease (AD) trial, in which patients

continued to show statistically significant benefits on all five

clinical endpoints studied;

-- Completed a comprehensive Phase 1 clinical development program in the

U.S., which continued to show Dimebon to be safe and well tolerated;

-- Completed a successful end-of-Phase 2 meeting with the U.S. Food and

Drug Administration, which recognized our previously completed AD trial

as pivotal and allowed us to proceed to a confirmatory pivotal Phase 3

trial;

Huntington's Disease

-- In collaboration with the Huntington Study Group, began a randomized,

double-blinded, placebo-controlled Phase 1-2 trial
'/>"/>